Weimin Mao
Guangxi University(CN)Guangxi Medical University(CN)China University of Petroleum, Beijing(CN)Beijing Jiaotong University(CN)Chang'an University(CN)Wenzhou Medical University(CN)Riverside University Health System - Medical Center(US)Jiangxi Provincial Cancer Hospital(CN)Zhejiang Cancer Hospital(CN)First Affiliated Hospital of GuangXi Medical University(CN)Hangzhou Cancer Hospital(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Esophageal Cancer Research and Treatment, Lung Cancer Diagnosis and Treatment, Gastric Cancer Management and Outcomes, Lung Cancer Research Studies
Most-Cited Works
- → Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial(2018)947 cited
- → Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study(2017)524 cited
- → Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma(2021)326 cited
- → Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial(2018)291 cited
- → Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial(2020)269 cited